6/28/23, 9:57 PM EMPULSE Pathway Feedback Search Clinical Topics Home Studies EMPULSE EMPULSE Disease Heart failure Trial question What is the role of empagliflozin in patients hospitalized for acute HF? Study design Multi-center Double blinded RCT Population Characteristics of study participants 34.0% female N = 530 66.0% male 530 patients (179 female, 351 male) Inclusion criteria: patients with a primary diagnosis of acute de novo or decompensated chronic HF regardless of LVEF Key exclusion criteria: cardiogenic shock; PE; current hospitalization for acute HF primarily triggered by PE, cerebrovascular accident, or acute myocardial infarction Interventions N=265 empagliflozin (at a dose of 10 mg/day) N=265 placebo (matching placebo) Primary outcome Clinical benefit at day 90 53.9 % 53.89 40.4 % 39.71 https://web.pathway.md/studies/recvh6mbcKUlUutnH 1/2 6/28/23, 9:57 PM EMPULSE Pathway 26.9 % Significant increase 13.5 % NNH = 7 0.0 % Empagliflozin Placebo Significant increase in clinical benefit at day 90 (53.89% vs. 39.71%; AD 14%, 95% CI 4.14 to 23.86) Secondary outcomes No significant difference in cardiovascular death or hospitalization for HF (12.8% vs. 18.5%; HR 0.69, 95% CI 0.45 to 1.08) No significant difference in improvement of 10 points in Kansas City Cardiomyopathy Questionnaire-total symptom score at day 90 (83.1% vs. 76.3%; OR 1.522, 95% CI 0.93 to 2.5) Significant increase in improvement in Kansas City Cardiomyopathy Questionnaire-total symptom score at day 90 (36.19 vs. 31.73; AD 4.45, 95% CI 0.32 to 8.59) Safety outcomes No significant difference in serious adverse events. Conclusion In patients with a primary diagnosis of acute de novo or decompensated chronic HF regardless of LVEF, empagliflozin was superior to placebo with respect to clinical benefit at day 90. Reference Adriaan A Voors, Christiane E Angermann, John R Teerlink et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 Mar;28(3):568-574. Open reference URL https://web.pathway.md/studies/recvh6mbcKUlUutnH 2/2